Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), sold 166,182 shares of the company's stock on August 28, 2026. The transactions, executed at an average price of $35.63 per share, totaled approximately $5.92 million.
This sale follows other recent insider transactions at Roivant Sciences, including multiple sales by Mayukh Sukhatme and an additional sale by Venker himself on the same day.
Insider selling activity can be attributed to a variety of reasons, such as portfolio diversification, tax planning, or adherence to pre-arranged trading plans. Such sales do not necessarily indicate a negative outlook on the company's future performance.